RxDoctor Payments Data

Andrew Reish, MD

Physical Medicine & Rehabilitation · Allentown, PANPI 1841426483

Payments from drug & device makers

$1,023in general payments, 2019–2025

Across 30 payments — averaging $34.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$427
  • Ipsen Biopharmaceuticals, Inc$295
  • AbbVie$136
  • Dynasplint Systems Inc.$64
  • Merz Pharmaceuticals, LLC$24
  • Amgen$22
  • plus $55 from 3 others

What the payments were for

  • Food & beverage$1,023100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic5$427
Ipsen Biopharmaceuticals, Inc13$295
AbbVie6$136
Dynasplint Systems Inc.1$64
Merz Pharmaceuticals, LLC1$24
Amgen1$22
Johnson & Johnson1$22
Piramal Critical Care1$17
Pfizer1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,023 in reported general payments places this provider in the 75th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.

See all physical medicine & rehabilitation providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$435,397
Medicare patients
419
Services billed
40,379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina38$84,890
DysportAbobotulinumtoxina15$22,485
Baclofen108$3,048
Tizanidine Hcl26$2,563
Gabapentin64$634
Pregabalin49$556
Duloxetine Hcl20$333
Diazepam30$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$136$84,89038 claims
Ipsen Biopharmaceuticals, IncDysport$295$22,48515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.

Other physical medicine & rehabilitation in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →